1
Return

An Optimal Spray Device for the Nose-to-Brain Delivery of AmyP53, an Adaptive Therapeutic Peptide for Alzheimer’s and Parkinson’s Diseases

delete2026-08-11
delete0
delete
OA
AI
G
Gonçalo Farias
H
Henri Chahinian
N
Nathalie Hauchard
D
Dominique Brunet
J
Jacques Fantini
N
Nouara Yahi
D
Driss Fantini
A
Anaïs Aulas *
DOI:10.3390/pharmaceutics18080987delete
deleteOriginal
deleteOriginal request for help
deleteShare
deleteSave
Abstract

Abstract

En 中文
Background: Nose-to-brain delivery offers a noninvasive route to bypass the blood–brain barrier for the treatment of neurodegenerative diseases. AmyP53 is a first-in-class adaptive 12-mer peptide that prevents the formation of neurotoxic amyloid oligomers by competitively targeting lipid raft gangliosides on brain cell membranes, thereby blocking the shared pathological mechanism underlying both Alzheimer’s and Parkinson’s diseases. Objective: Here, we report the identification of optimal spray devices for the nose-to-brain delivery of AmyP53, ahead of a planned Phase 1 clinical trial. Method/Results: Among six devices evaluated (four commercial systems and two novel devices specifically engineered for nose-to-brain delivery), two systems were identified as optimal for further clinical development (narrower plume angles and significantly higher deposition in the olfactory region): the Neurospray™ and Neurospray™ Preservative-Free (PF). AmyP53 was quantitatively and reproducibly delivered by both Neurospray™ systems, retaining full recognition of its therapeutic target (gangliosides), as assessed by a surface pressure-based ganglioside-binding assay. In a rabbit preclinical model, intranasal administration of AmyP53 with the Neurospray™ resulted in rapid and sustained brain delivery, detectable at 10 min and persisting at 24 h post-administration, without significant systemic exposure. Conclusions: These results validate the Neurospray™ drug delivery systems as optimal drug delivery systems for the clinical development of AmyP53.
Keywords:
AmyP53
nose to brain
Alzheimer
Parkinson
oligomers
ganglioside
therapy

Journal

Pharmaceutics cover
Pharmaceutics
IF:
5.5
Papers:
1.4W
Citations:
6.2W

Organization

A
aix-marseille university
Scholars:
362
Papers: 188
Citations: 1
A
aptar pharma
Scholars:
5
Papers: 3
Citations: 0
A
amypore
Scholars:
3
Papers: 1
Citations: 0
Cited Papers

Cited Papers

Citing Papers

Citing Papers